A British research team analyzed the health status data of more than 2.5 million people in Scotland who received the first dose of anti-Covid serum and revealed this in a study published in the journal Nature Medicine.
The first dose of AstraZeneca’s Covid vaccine is linked to a slight increase in the risk of developing new coronary pneumonia Bleeding disorders Caused by a decrease in the number of platelets, called Thrombocytopenia immunity (Or immune thrombocytopenic purpura, ITP).A British research team discovered this in a study published in the journal Natural medicine After analyzing the health data of 2.53 million vaccinated adults in Scotland, 1.71 million of them received the first dose of serum developed by Oxford University, and 820,000 received the serum produced by Pfizer Biotech. The investigation did not find that Pfizer’s BioNTech vaccine increased the risk of thrombocytopenia, venous thromboembolism, or bleeding events.
AstraZeneca linked to increased risk of bleeding
AstraZeneca vaccines have been affected by conflicting decisions by international drug agencies (not yet authorized for use in the United States, but have been approved by the European Medicines Agency (EMA) and the UK regulatory agency (MHRA) and other agencies) in non-European countries) It is the core of the safety issue, because in young people, especially women, rare cases of thrombosis related to platelet deficiency have occurred, which has caused various authorities to restrict use to certain age groups or stop dosing completely.
However, the new analysis led by Aziz Sheikh of the University of Edinburgh did not observe an association between these thromboembolic events and vaccination, but instead emphasized a risk”Important but very rare“Immune thrombocytopenia, in fact, is the opposite reaction to thrombosis as an adverse event after vaccination.”Our studio -Researcher said- Shows that the risk of this very rare adverse event with the AstraZeneca vaccine may increase, which is similar to other vaccines (including hepatitis B vaccine); measles, mumps and rubella; and influenza“.
In terms of morbidity, it is approximately 1.13 cases of immune thrombocytopenia every 100,000 inoculationsThe condition is caused by the formation of antibodies that destroy platelets in the body. It can appear as sudden or gradual symptoms. The first signs of a decrease in platelet count can lead to skin bleeding-usually tiny red spots (peech spots and petechiae on the skin on the legs Minor trauma can cause bruising (ecchymosis or blue-black purpura). In severe cases, the digestive tract may lose a lot of blood, or there may be life-threatening cerebral hemorrhage.
“This very small risk is important, but it must be viewed in the context of the very obvious benefits of the vaccine“Adding researchers, plans to update the analysis with the expansion of vaccination activities and the availability of new vaccines.”We also plan to expand our pharmacovigilance work to assess Results of the second dose These and other vaccines“.